Neuroleptic malignant syndrome in the multiple trauma patient.
A 25-year-old multiply traumatized patient developed neuroleptic malignant syndrome (NMS) secondary to the use of Haldol. The diagnosis was delayed due to poor recognition of the syndrome, risking a fatal outcome. The signs and symptoms of the syndrome are presented along with the pathophysiology and the available treatments for NMS.
Quinn
D E
DE
Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pennsylvania.
Goodman
M A
MA
D000328:Adult; D003402:Creatine Kinase / Q000097:blood; D003937:Diagnosis, Differential; D006220:Haloperidol / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009104:Multiple Trauma / Q000150:complications* / Q000188:drug therapy; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology* / Q000503:physiopathology; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy
D003402:Creatine Kinase; D006220:Haloperidol